Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Roxee Medication Guide

Deracoxib

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Chewable Tablets Multiple FDA labelers Official label facts Owner quick guide first

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Jun 22, 2026, 10:41 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Jun 22, 2026, 10:41 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Jun 13, 2026, 11:29 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Image coming soon
Deracoxib

Deracoxib

Drug type: Generic ingredient • Branded profile FDA branded products available

Both Chewable Tablets Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Deracoxib

DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs. Species commonly shown: Both, Dog.

Generic name
Deracoxib
Brand names
Deramaxx® Chewable Tablets, Doxidyl™, Deracoxib Chewable Tablets, NA
Manufacturer
Multiple FDA labelers
Species
Both, Dog
Dosage forms
Chewable Tablets
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Deramaxx® Chewable Tablets Doxidyl™ Deracoxib Chewable Tablets NA DOXIDYL Chewable Rederox Deramaxx Deracoxib OstiMax Chewable Coxiba
Dosage forms
Chewable Tablets

Indications / Uses

DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Warnings / Contraindications

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

  • Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Other abnormal test result NOS, Diarrhoea, Elevated blood urea nitrogen (BUN), Death by euthanasia.

FAQ

Both, Dog

Yes. Roxee shows this as prescription-only.

Chewable Tablets

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the control of pain and inflammation associated with osteoarthritis, for the control of postoperative pain and inflammation associated with orthopedic surgery, and for the control of postoperative pain and inflammati...

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg
  • Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets
  • For oral use in dogs only
  • Do not use in cats
  • Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian
  • Vomiting (1 reports)
  • wobbly/unsteady walking (1 reports)
  • Low platelet count (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Deracoxib; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-074601
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 26 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-074601
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-074601
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Vomiting (1 reports), Unsteady walking (ataxia) (1 reports), Low platelet count (1 reports), Limping (1 reports), Limb non-weight bearing (1 reports)

Body systems represented Signal grouping

Digestive (4), Neurologic (3), Effectiveness (1), Other (24)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (28 reports), Cat (4 reports)

Breed metadata in reports Metadata only

Retriever - Labrador (2), ['Shepherd (unspecified)', 'Dog (unknown)'] (2), Chihuahua (1), Terrier - Bull - American Pit (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Deracoxib fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg table, Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets, For oral use in dogs only, Do not use in cats, Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Deracoxib brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-074601 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. Labeling · document · documents
  8. Labeling · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg
  • Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets
  • For oral use in dogs only
  • Do not use in cats
  • Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian

Most reported reactions:

  • Vomiting (1 reports)
  • Unsteady walking (ataxia) (1 reports)
  • Low platelet count (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Dog
Indication / use
For the control of pain and inflammation associated with osteoarthritis, for the control of postoperative pain and inflammation associated with orthopedic surgery, and for the con…
Form / route / dose
Form: Chewable Tablets
Route: Oral
Confirm product label and patient-specific plan.
Warnings
  • High: Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be bro…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Chewable Tablets
Identifiers:
ANADA: 200637 ANADA: 200704 NADA: 141203 NDC Package: 11695-6995-1 NDC Package: 11695-6995-2 NDC Package: 11695-6996-1 NDC Package: 11695-6996-2 NDC Package: 11695-6997-1 NDC Package: 11695-6997-2 NDC Package: 11695-6998-1 NDC Package: 11695-6998-2 NDC Package: 13744-530-01 NDC Package: 13744-530-02 NDC Package: 13744-531-01 NDC Package: 13744-531-02 NDC Package: 13744-532-01 NDC Package: 13744-532-02 NDC Package: 13744-533-01 NDC Package: 13744-533-02 NDC Package: 13985-958-30
Source metadata:

Warnings / Contraindications

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
7
Matching reports
2
Active filters
2
Selected filters
Reaction: Conjunctivitis Clear Body system: Effectiveness Clear
Reset
Showing up to 50 matching reports.

USA-USFDACVM-2025-US-073723

Received 2025-11-25 · MSK · MSK

Serious
Species
Dog
Breed
['Shepherd (unspecified)', 'Dog (unknown)']
Age
Under 1 year (11 Month)
Sex
Female Unknown
Region
USA
Reactions
FractureThrombocytopeniaRespiratory tract infection NOSConjunctivitisUnclassifiable adverse eventOther abnormal test result NOSLack of efficacy (endoparasite) - tapeworm
Body systems
OtherEffectiveness
Outcomes
Outcome Unknown

USA-USFDACVM-2025-US-068774

Received 2025-11-19 · MSK · MSK

Serious
Species
Dog
Breed
['Shepherd (unspecified)', 'Dog (unknown)']
Age
Under 1 year (11 Month)
Sex
Female Intact
Region
USA
Reactions
FractureThrombocytopeniaRespiratory tract infection NOSConjunctivitisUnclassifiable adverse eventOther abnormal test result NOSLack of efficacy (endoparasite) - tapeworm
Body systems
OtherEffectiveness
Outcomes
Outcome Unknown

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
26
Species represented
2
Grouped by Body System
Digestive (4) · Vomiting, Loss of appetite, Diarrhea Neurologic (3) · Unsteady walking (ataxia), Tiredness (lethargy), Head tilt - neurological disorder Effectiveness (1) · Lack of efficacy (endoparasite) - tapeworm Other (24) · Low platelet count, Limping, Limb non-weight bearing
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Neurologic 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Effectiveness 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (28) Cat (4)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Neurologic Cat Non-serious - 1
Other Dog Serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Effectiveness Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Neurologic Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

6

SPL

11

FOI

7

A-200704-C-0013-NL-AA_CIS.pdf

Official label / PI · Labeling

A-200704-C-0013-NL-AA_PI.pdf

Official label / PI · Labeling

N-141203-C-0145-NL-AA_CIS.pdf

Official label / PI · Labeling

N-141203-C-0145-NL-AA_PI.pdf

Official label / PI · Labeling

Doxidyl Approved M Labeling-Insert.pdf

Official label / PI · Labeling

Doxidyl Approved M Labeling-Insert.pdf

Official label / PI · Labeling

Deracoxib Chewable Tablets

SPL · SPL

FDA Structured Product Label

Deracoxib Chewable Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Felix Pharmaceuticals Pvt. Ltd.
ANADA
200-704
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
12 mg, 25 mg, 75 mg, or 100 mg of deracoxib per tablet

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis, for the control of postoperative pain and inflammation associated with orthopedic surgery, and for the control of postoperative pain and inflammation associated with dental surgery.

Dosage

Osteoarthritis Pain and Inflammation: 0.45 - 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, as needed.

Postoperative Orthopedic Pain and Inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration.

Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.

Deramaxx® Chewable Tablets

SPL · SPL

FDA Structured Product Label

Deramaxx® Chewable Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Elanco US Inc.
NADA
141-203
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
Each chewable tablet contains 12, 25, 50, 75, or 100 milligrams (mg) deracoxib.

Dogs

Indication
DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs.
Dosage
0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.
Indication
DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs.
Dosage
1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.
Indication
DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Dosage
0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/ day) as a single daily dose, as needed.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

Doxidyl™

SPL · SPL

FDA Structured Product Label

Doxidyl™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Ceva Sante Animale
ANADA
200-637
Status
RX
Form
Chewable Tablets
Route
Oral
Species
Dog
Composition / specifications
12 mg, 25 mg, 75 mg or 100 mg deracoxib

Dogs

Indication

For the control of pain and inflammation associated with osteoarthritis in dogs, for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs, and for the control of postoperative pain and inflammation associated with dental surgery in dogs.

Dosage

Osteoarthritis Pain and Inflammation: 0.45-0.91 mg/lb/day (1 to 2 mg/kg/day) as a single dose, as needed. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Postoperative Orthopedic Pain and Inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days. The first dose should be given approximately 1 hour prior to dental surgery and subsequent doses should be given daily for up to two additional treatments. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Deracoxib SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Deracoxib. Use the source link for the full official labeling record.

Rederox SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Rederox. Use the source link for the full official labeling record.

OstiMax Chewable SPL

SPL · Structured Product Label

FDA Structured Product Label XML for OstiMax Chewable. Use the source link for the full official labeling record.

Deracoxib SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Deracoxib. Use the source link for the full official labeling record.

Deramaxx SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Deramaxx. Use the source link for the full official labeling record.

Coxiba SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Coxiba. Use the source link for the full official labeling record.

DOXIDYL Chewable SPL

SPL · Structured Product Label

FDA Structured Product Label XML for DOXIDYL Chewable. Use the source link for the full official labeling record.

NA SPL

SPL · Structured Product Label

FDA Structured Product Label XML for NA. Use the source link for the full official labeling record.

FOI Summary oA 200-704 Approved June 14, 2021.pdf

FOI · FOI

UCM292023.pdf

FOI · FOI

ucm117650.pdf

FOI · FOI

ucm117647.pdf

FOI · FOI

ucm117645.pdf

FOI · FOI

ucm117640.pdf

FOI · FOI

FOI Summary oA 200-637 Approved February 4, 2019.pdf

FOI · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Coxiba DOXIDYL Chewable Deracoxib Deramaxx NA OstiMax Chewable Rederox
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Chewable Tablets Oral
Applications: ANADA 200-704 • NADA 141-203 • ANADA 200-637
NDC: Packages 11695-6995-1 11695-6995-2 11695-6996-1 11695-6996-2 11695-6997-1 11695-6997-2 Products 11695 13744 13985 17033 46066 58198
Documents: 13 (FOI: 7) • SPL: 3 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 21 Cat 0 View
Case summaries: 7 (showing 7) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes
ICD10_CM: M19.90
Unspecified osteoarthritis, unspecified site

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Vomiting (1) Unsteady walking (ataxia) (1) Low platelet count (1) Limping (1) Limb non-weight bearing (1) Lack of efficacy (endoparasite) - tapeworm (1) Inappropriate urination (1) Inappropriate defecation (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200637 ANADA: 200704 NADA: 141203 NDC Package: 11695-6995-1 NDC Package: 11695-6995-2 NDC Package: 11695-6996-1 NDC Package: 11695-6996-2 NDC Package: 11695-6997-1 NDC Package: 11695-6997-2 NDC Package: 11695-6998-1 NDC Package: 11695-6998-2 NDC Package: 13744-530-01 NDC Package: 13744-530-02 NDC Package: 13744-531-01 NDC Package: 13744-531-02 NDC Package: 13744-532-01 NDC Package: 13744-532-02 NDC Package: 13744-533-01 NDC Package: 13744-533-02 NDC Package: 13985-958-30 NDC Package: 13985-958-90 NDC Package: 13985-959-30 NDC Package: 13985-959-90 NDC Package: 13985-960-30
Package NDC Product NDC Form / Route Status
11695-6995-1 11695 -
11695-6995-2 11695 -
11695-6996-1 11695 -
11695-6996-2 11695 -
11695-6997-1 11695 -
11695-6997-2 11695 -
11695-6998-1 11695 -
11695-6998-2 11695 -
13744-530-01 13744 -
13744-530-02 13744 -
13744-531-01 13744 -
13744-531-02 13744 -
13744-532-01 13744 -
13744-532-02 13744 -
13744-533-01 13744 -
13744-533-02 13744 -
13985-958-30 13985 -
13985-958-90 13985 -
13985-959-30 13985 -
13985-959-90 13985 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Deracoxib SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Rederox SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • OstiMax Chewable SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Deracoxib SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Deramaxx SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • Coxiba SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • DOXIDYL Chewable SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • NA SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • A-200704-C-0013-NL-AA_PI.pdf • Official label • Official • Nov. 14, 2023
    FDA official labeling for application 200704
  • A-200704-C-0013-NL-AA_CIS.pdf • Official label • Official • Nov. 14, 2023
    FDA official labeling for application 200704
  • FOI Summary oA 200-704 Approved June 14, 2021.pdf • FOI summary • Official • Nov. 14, 2023
    FDA FOI summary for application 200704
  • N-141203-C-0145-NL-AA_PI.pdf • Official label • Official • April 8, 2020
    FDA official labeling for application 141203
  • N-141203-C-0145-NL-AA_CIS.pdf • Official label • Official • April 8, 2020
    FDA official labeling for application 141203
  • ucm117640.pdf • FOI summary • Official • April 8, 2020
    FDA FOI summary for application 141203
  • ucm117645.pdf • FOI summary • Official • April 8, 2020
    FDA FOI summary for application 141203
  • ucm117647.pdf • FOI summary • Official • April 8, 2020
    FDA FOI summary for application 141203
  • ucm117650.pdf • FOI summary • Official • April 8, 2020
    FDA FOI summary for application 141203
  • UCM292023.pdf • FOI summary • Official • April 8, 2020
    FDA FOI summary for application 141203
  • Doxidyl Approved M Labeling-Insert.pdf • Official label • Official • Oct. 29, 2019
    FDA official labeling for application 200637
  • Doxidyl Approved M Labeling-Insert.pdf • Official label • Official • Oct. 29, 2019
    FDA official labeling for application 200637
  • FOI Summary oA 200-637 Approved February 4, 2019.pdf • FOI summary • Official • Oct. 29, 2019
    FDA FOI summary for application 200637

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 140 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Other abnormal test result NOS, Diarrhoea,… (Clinical, 2026-04-11)
  • contraindications: Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not atte… (Official, 2026-04-12)
  • contraindications: Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not atte… (Official, 2026-04-11)
  • contraindications: Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not atte… (Official, 2026-02-12)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-22)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-22)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-21)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-20)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-13)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-12)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-12)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-11)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-11)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-10)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-09)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-08)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-07)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-06)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-05)
  • indications: DERAMAXX™ Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs > 4 lbs (1.8 kg). Fo… (Official, 2026-06-04)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Deracoxib Chewable Tablets
RX
Deracoxib
Chewable Tablets Oral
Felix Pharmaceuticals Pvt. Ltd. ANADA 200-704 Approved Nov 14, 2023
Deramaxx® Chewable Tablets
RX
Deracoxib
Chewable Tablets Oral
Elanco US Inc. NADA 141-203 Approved Apr 8, 2020
Doxidyl™
RX
Deracoxib
Chewable Tablets Oral
Ceva Sante Animale ANADA 200-637 Approved Oct 29, 2019

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
12 mg, 25 mg, 75 mg, or 100 mg of deracoxib per tablet
Dogs
Indication

For the control of pain and inflammation associated with osteoarthritis, for the control of postoperative pain and inflammation associated with orthopedic surgery, and for the control of postoperative pain and inflammation associated with dental surgery.

Dosage

Osteoarthritis Pain and Inflammation: 0.45 - 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, as needed.

Postoperative Orthopedic Pain and Inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration.

Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
Each chewable tablet contains 12, 25, 50, 75, or 100 milligrams (mg) deracoxib.
Dogs
Indication
DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs.
Dosage
0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.
Indication
DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs.
Dosage
1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.
Indication
DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Dosage
0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/ day) as a single daily dose, as needed.
Limitations
Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
12 mg, 25 mg, 75 mg or 100 mg deracoxib
Dogs
Indication

For the control of pain and inflammation associated with osteoarthritis in dogs, for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs, and for the control of postoperative pain and inflammation associated with dental surgery in dogs.

Dosage

Osteoarthritis Pain and Inflammation: 0.45-0.91 mg/lb/day (1 to 2 mg/kg/day) as a single dose, as needed. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Postoperative Orthopedic Pain and Inflammation: 1.4 – 1.8 mg/lb/day (3 to 4 mg/kg/day) as a single daily dose, as needed, not to exceed 7 days of administration. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Postoperative Dental Pain and Inflammation: 0.45 – 0.91 mg/lb/day (1 to 2 mg/kg/day) as a single daily dose, for 3 days. The first dose should be given approximately 1 hour prior to dental surgery and subsequent doses should be given daily for up to two additional treatments. Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets.

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with dental surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of postoperative pain and inflammation associated with orthopedic surgery in dogs. DERAMAXX Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Dogs needing a dose of less than 12.5 mg can only be accurately dosed through use of the 12 mg tablet, which can be broken in half to provide 6 mg. Do not attempt to accurately dose smaller dogs through the use of breaking larger tablets. For oral use in dogs only. Do not use in cats. Federal Law (U.S.) restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Loss of appetite (1) • Dog Diarrhea (1) • Dog Blood in vomit (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog Tiredness (1) • Cat Head tilt - neurological disorder (1) • Dog

Showing top 5 for Neurologic.

Effectiveness
Lack of efficacy (endoparasite) - tapeworm (1) • Dog

Showing top 5 for Effectiveness.

Other
Low platelet count (1) • Dog Limping (1) • Dog Limb non-weight bearing (1) • Dog Labeled drug-species interaction (1) • Cat Knuckling (1) • Dog
Show more (19)
Inappropriate urination (1) • Dog Inappropriate defecation (1) • Dog Inappetence (1) • Dog Horizontal nystagmus (1) • Dog General illness (1) • Dog Fracture (1) • Dog Falling (1) • Dog Elevated creatinine (1) • Dog Ecchymosis (1) • Cat Discomfort NOS (1) • Dog Decreased haematocrit (1) • Dog Death by euthanasia (1) • Dog Death (1) • Dog Conjunctivitis (1) • Dog Bone and joint disorder NOS (1) • Dog Bloody stool (1) • Dog Arthritis (1) • Dog Accidental exposure (1) • Cat Abnormal radiograph finding (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Retriever - Labrador, Male, 5 year, 39.463 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Limb non-weight bearing, Bone and joint disorder NOS, Other abnormal test result NOS, Abnormal radiograph finding, Urinary tract obstruction/blockage… • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2025-US-074601
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 39.463 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Limb non-weight bearing Bone and joint disorder NOS Other abnormal test result NOS Abnormal radiograph finding Urinary tract obstruction/blockage Discomfort NOS Walking difficulty Death by euthanasia Osteochondritis dissecans Urolithiasis
Outcomes: Euthanized

Dog, Chihuahua, Female, 18 year, 3.774 kilogram • Drug: MSK, Tablet, chewable, Unknown • Reactions: Knuckling, Overdose • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072836
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 18.00 Year
  • Weight: 3.774 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet, chewable
Reactions Reported:
Knuckling Overdose
Outcomes: Ongoing

Dog, Terrier - Bull - American Pit, Female, 10 year, 30.164 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Partial lack of efficacy • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-072783
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 30.164 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Partial lack of efficacy
Outcomes: Ongoing

Dog, ['Hound (unspecified)', 'Dog (unknown)'], Female, 9 year, 13.78 kilogram • Drug: MSK, Unknown • Reactions: Diarrhea • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-072352
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 9.00 Year
  • Weight: 13.780 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Diarrhea
Outcomes: Outcome Unknown

Dog, Retriever - Labrador, Female, 14 year, 31.8 kilogram • Drug: MSK, Oral • Reactions: Watery diarrhoea • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-073465
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 14.00 Year
  • Weight: 31.800 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
Reactions Reported:
Watery diarrhoea
Outcomes: Outcome Unknown

Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Female, 11 month • Drug: MSK, Unknown • Reactions: Fracture, Thrombocytopenia, Respiratory tract infection NOS, Conjunctivitis, Unclassifiable adverse event… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-073723
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Month
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Fracture Thrombocytopenia Respiratory tract infection NOS Conjunctivitis Unclassifiable adverse event Other abnormal test result NOS Lack of efficacy (endoparasite) - tapeworm
Outcomes: Outcome Unknown

Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Female, 11 month • Drug: MSK, Unknown • Reactions: Fracture, Thrombocytopenia, Respiratory tract infection NOS, Conjunctivitis, Unclassifiable adverse event… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-068774
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.00 Month
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Fracture Thrombocytopenia Respiratory tract infection NOS Conjunctivitis Unclassifiable adverse event Other abnormal test result NOS Lack of efficacy (endoparasite) - tapeworm
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.